1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsLLS Therapy Acceleration Program (TAP) is sponsored by Leukemia & Lymphoma Society (LLS). A strategic venture philanthropy initiative that co-funds first-in-human and registration-enabling clinical trials for blood cancers.
Get alerted about grants like this
Save a search for “Leukemia & Lymphoma Society (LLS)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Therapy Acceleration Program - How to Apply | Leukemia and Lymphoma Society Therapy Acceleration Program How to Apply & Support TAP Therapy Acceleration Program How to Apply & Support TAP TAP accepts and reviews partnering inquiries year round!
TAP collaborates with and makes equity investments in biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations and orphan indications. Click here to download the initial inquiry form Send completed inquiry form & non-confidential presentation to Dr. Blaine Robinson , Vice President, Therapy Acceleration Program®.
Want to know more about applying to TAP - download a presentation and a one-pager for more information. Listen to a network of experts share their insights and experience on TAP. Interested in learning how a donation can help support & impact TAP?
Through TAP, investment-savvy donors provide opportunity funding to enable LLS to make equity investments in biotech companies with novel therapeutic projects—with the potential for a significant return back to LLS. This return comes in many forms: in advances in the field, improved therapies, new standards of care and innovative technologies that transform the entire landscape of medical science and cancer therapeutics.
Returns are also seen in the ability of TAP biotech partners to raise additional funds to advance new therapies towards approvals, and in the financial returns that come back to LLS to re-invest in TAP. For more information on how to support TAP, please contact Sheena Mehta, Director of Philanthropy, TAP ( sheena. mehta@lls.
org ). Download our Impact Investing Brochure for additional information. How did TAP impact the development of Elzonris?
LLS awarded several grants to Dr. Arthur Frankel between 1998-2008 to develop fusion protein therapies for blood cancers, including SL-401 (now known as Elzonris). TAP then partnered with Stemline Therapeutics in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Listen to what Dr. Arthur Frankel and Peter MacDonald, SVP of Corporate & Business Development of Stemline Therapeutics, have to say about LLS, the role TAP played in the development of Elzonris and the value TAP created for Stemline beyond the funding amount. Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
The TAP team applies industry expertise and a rigorous due diligence to identify companies that are best positioned to advance novel research and therapeutic technologies in areas with the greatest potential impact on patients. Every year, TAP reviews opportunities from approximately 80-100 biotech companies and only invests in several new projects annually, with an open partnering cycle all year long.
Diligence typically takes 3-6 months, but varies based on company responsiveness to LLS requests.
Based on current listing details, eligibility includes: Biotechnology companies developing therapeutics for leukemia, lymphoma, or myeloma. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $500,000 - $9,000,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.